ABI
CLDX icon

Adamant Biomedical Investments’s Celldex Therapeutics CLDX Stock Holding History

Adamant Biomedical Investments’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		$548K Hold
2,000
– – 0.13% 91
2014
Q3 		$389K Buy
+2,000
New +$436K 0.1% 90

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 17.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Adamant Biomedical Investments's CLDX Position: Q4 2014 in Review

Adamant Biomedical Investments held its Celldex Therapeutics (CLDX) position steady in Q4 2014 at 2,000 shares worth $548K. The position accounts for 0.13% of the portfolio, ranked #91.

Adamant Biomedical Investments first reported a position in CLDX in Q3 2014 and has held it in 2 quarters since. 163 funds tracked by Wall St. Rank hold CLDX as of Q4 2014.

  • Adamant Biomedical Investments held 2,000 shares of Celldex Therapeutics worth $548K as of Q4 2014.
  • Adamant Biomedical Investments left its Celldex Therapeutics share count unchanged in Q4 2014.
  • Celldex Therapeutics made up 0.13% of Adamant Biomedical Investments's portfolio in Q4 2014, its #91 holding.
  • Adamant Biomedical Investments first reported a position in Celldex Therapeutics in Q3 2014 and has held it in 2 quarters since.
  • 163 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2014.

Based on Adamant Biomedical Investments's 13F filing for Q4 2014, filed 13 Feb 2015.